Comparison of PSA Response to Generic Versus Innovator (Zytiga) Formulations of Abiraterone in Metastatic CRPC: A Retrospective Analysis
Indian Journal of Medical and Paediatric Oncology · 01.08.2025 · 46 (04) · 363-369
DOI: 10.1055/s-0044-1782235 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Medical and Paediatric Oncology, erschienen am 01.08.2025. Verfasst von Sharath Kumar und 7 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Abiraterone acetate has been shown to enhance overall survival and radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC). Presently, multiple generic brands of abiraterone are accessible in India. Nevertheless, evidence supporting the clinical equivalence of these generics when compared to the innovator has not been established, and thus, questions regarding their quality persist.
Objectives
This retrospective analysis aimed to compare the prostate-specific antigen (PSA) response in patients receiving generic or innovator (Zytiga) abiraterone for mCRPC. Materials and Methods This was a single-center, retrospective, comparative study. All relevant data from selected cases were collected from the hospital's electronic medical record (EMR). Patients with mCRPC, treated with either innovator or generic abiraterone from 2010 to 2019 and followed up until disease progression/death, were included. Patients who switched between generic and reference brands and vice versa were excluded. Patients in both arms were matched for prior treatment with docetaxel (yes/no), age at cancer diagnosis (>60, ≤60 years), and total Gleason's score (≥8,
Zitieren
APA
Kumar, S., Joshi, A., Takke, A., Varghese, D., Pathak, S., Noronha, V., Prabhash, K., & Gota, V. (2025). Comparison of PSA Response to Generic Versus Innovator (Zytiga) Formulations of Abiraterone in Metastatic CRPC: A Retrospective Analysis. Indian Journal of Medical and Paediatric Oncology, 46(04), 363-369. https://doi.org/10.1055/s-0044-1782235
Vancouver
Kumar S, Joshi A, Takke A, Varghese D, Pathak S, Noronha V, et al. Comparison of PSA Response to Generic Versus Innovator (Zytiga) Formulations of Abiraterone in Metastatic CRPC: A Retrospective Analysis. Indian Journal of Medical and Paediatric Oncology. 2025;46(04):363-369. doi:10.1055/s-0044-1782235
BibTeX
@article{Kumar2025,
author = {Kumar, Sharath and Joshi, Amit and Takke, Apurva and Varghese, Diana and Pathak, Shruti and Noronha, Vanita and Prabhash, Kumar and Gota, Vikram},
title = {Comparison of PSA Response to Generic Versus Innovator (Zytiga) Formulations of Abiraterone in Metastatic CRPC: A Retrospective Analysis},
journal = {Indian Journal of Medical and Paediatric Oncology},
year = {2025},
volume = {46},
number = {04},
pages = {363--369},
doi = {10.1055/s-0044-1782235}
}
EUVIMED